Overcoming Resistance to Targeted Anticancer Drugs
Mené sur 449 patients atteints d'une leucémie myéloïde chronique ou d'une leucémie lymphoblastique aiguë Ph+ résistante au dasatinib ou au nilotinib, cet essai de phase II évalue l'activité antitumorale et la toxicité du ponatinib (durée médiane de suivi : 15 mois)
More than a decade ago, imatinib, an agent that has a specific inhibitory interaction with the BCR-ABL fusion protein, was introduced for the treatment of chronic myeloid leukemia (CML). The introduction of this agent dramatically changed researchers' understanding not only of the role of tyrosine kinases as targets for oncology drugs (despite the conserved status of protein kinase domains in nature), but also their ability to conceptualize and test novel molecular mechanisms of action and drug resistance in solid tumors such as adenocarcinoma of the lung as well as in hematopoietic cancers. The underlying genetic instability of most cancers . . .
New England Journal of Medicine , éditorial, 2012